“…Aspects of the structural biology of C5 are well understood, due to a crystal structure of the apo form (Fredslund et al, 2008) and a number of co-crystal structures of C5 with various modulators. By virtue of its constitutive role in the terminal pathway, C5 is a recurrent target for immune evasion molecules and structures have been solved of C5 in complex with an inhibitory molecule derived from Staphylococcus aureus, SSL-7 (Laursen et al, 2010), as well as several structurally distinct examples from ticks: OmCI (Jore et al, 2016), RaCI (Jore et al, 2016) and Cirp-T (Reichhardt et al, 2020). Additionally, the structures of C5 with the inhibitory monoclonal antibody (mAb) eculizumab (Schatz-Jakobsen et al, 2016), of C5 with a small molecule inhibitor (Jendza et al, 2019), and of C5 with the complement depleting agent Cobra Venom Factor (CVF) (Laursen et al, 2011), have all been determined.…”